glp-1 receptor agonists weight loss effectiveness for reduction in people living with obesity but without diabetes: a living benefit–harm modelling study New Research on GLP-1s &

Essentials: Full line up of supportive products for sleep, detoxing, protein addition, performance, and more

The Renal Hemodynamic Effects of the SGLT2 Inhibitor Dapagliflozin Are Caused by Post-Glomerular Vasodilatation Rather than Pre-Glomerular Vasoconstriction in Metformin-Treated Patients with Type 2 Diabetes in the Randomized, Double-Blind RED Trial

placebo: 2.44, 95% CI 1.29, 4.63) and elevated blood pressure (RR: 1.72, 95% CI 1.04, 2.85)

Weight loss data

GLP-1 therapiessuch as semaglutide and newer dual agonists like tirzepatidehave demonstrated substantial weight loss and metabolic benefits, far exceeding traditional therapies and supporting patients in diet and lifestyle changes